Advertisement

Interactions Between Conventional and Herbal Medicinal Products

  • Danielle Sevior
  • Jorma Ahokas
Chapter

Abstract

Drug interactions are a commonplace occurrence, and with the majority of pharmaceuticals, such interactions are well characterized. These interactions may be beneficial, with augmentation of the effects of one of the agents used. However, interactions with adverse outcomes are also common. Harmful interactions can result in therapeutic failure of a drug or in a toxic outcome. Just as two drugs can interact, so can complementary products and drugs; such interactions are referred to as “herb-drug interactions” and, like all drug interactions, can be potentially harmful. Herb-drug interactions present their unique additional complications due to the complex and variable nature of the products and their somewhat random use.

Investigations into herb-drug interactions are challenging due to the very nature of the product; many components that may be active or inactive when isolated may behave very differently when in a mixture. Additionally, there is great product variability and currently, regulations requiring standardization or demonstration of product safety, are carried out mainly in developed parts of the world. Also, the methodology used to study herb-drug interactions can have a significant impact on the results obtained, and an understanding of these methods and the extrapolation of the data to human impact is required.

In this chapter we discuss herb-drug interactions of potential or reported clinical significance.

Keywords

Herb-drug interactions Investigation methods Pharmacokinetics Adverse event reporting 

References

  1. Anubala S, Sekar R, Nagaiah K (2014) Development and validation of an analytical method for the separation and determination of major bioactive curcuminoids in curcuma longa rhizomes and herbal products using non-aqueous capillary electrophoresis. Talanta 123:10–17CrossRefPubMedGoogle Scholar
  2. Barnes P, Bloom B, Nahin R (2008) Complementary and alternative medicine use among adults and children: United States, 2007. National Health Statistics Report. U.S. Department of Health and Human ServicesGoogle Scholar
  3. Benzie IFF, Wachtel-Galor S (2011) Herbal medicine: bimolecular and clinical aspects. CRC Press/Taylor & Francis, FloridaCrossRefGoogle Scholar
  4. Brady JF, Xiao F, Wang MH, Li Y, Ning SM, Gapac JM, Yang CS (1991) Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes, and hepatotoxicity in rats. Toxicol Appl Pharmacol 108:366–373CrossRefPubMedGoogle Scholar
  5. Braun L, Cohen M (2010) Herbs & natural supplements − an evidence-based guide. Elsevier Australia (Sydney)Google Scholar
  6. Breckenridge A (2006) William Withering’s legacy − for the good of the patient. Clin Med 6:393–397CrossRefGoogle Scholar
  7. Chan K (1995) Progress in traditional Chinese medicine. Trends Pharmacol 16:182–187CrossRefGoogle Scholar
  8. Chan WK, Delucchi AB (2000) Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67:3103–3112CrossRefPubMedGoogle Scholar
  9. Coecke S, Pelkonen O, Leite S, Bernauer U, Bessems JGM, Bois FY, Gundert-Remy U, Loizou G, Testai E, Zaldivar JM (2013) Toxicokientics as a key to the integrated toxicity risk assessment based primarily on non-animal approaches. Toxicol In Vitro 27:1570–1577CrossRefPubMedGoogle Scholar
  10. Conney AH (1982) Induction of microsomal enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic hydrocarbons: G.H.A. Clowes memorial lecture. Cancer Res 42:4875–4917PubMedGoogle Scholar
  11. Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K (2000) St John’s wort induces intestinal P-glycoprtoein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 68:598–604CrossRefPubMedGoogle Scholar
  12. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay MI, Kessler RC (1998) Trends in alternative medicine use in the United States, 1990–1997. J Am Med Assoc 280:1569–1575CrossRefGoogle Scholar
  13. Evans WE, Relling MV (1999) Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286:487–491CrossRefPubMedGoogle Scholar
  14. Feely J, Stevenson I, Crooks J (1981) Alteres plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet 6:298–305CrossRefPubMedGoogle Scholar
  15. Fournier T, Medjoubi-N N, Porquet D (2000) Alpha-1- acid glycoprotein. Biochim Biophys Acta 1482:157–171CrossRefPubMedGoogle Scholar
  16. Garrard J, Harms S, Eberly LE, Matiak A (2003) Variations in product choices of frequently purchased herbs. Arch Intern Med 163:2290–2295CrossRefPubMedGoogle Scholar
  17. Office of Inspector General (2001) Adverse event reporting for dietary supplements. An inadequate safety valve. Department of Health and Human Services - USA. Boston Regional Office, OEI-01-00-00180. Available at: http://www.dhhs.gov/oig/oei
  18. Guengerich FP (2005) Human cytochrome P450 enzymes. In: Ortiz De Montellano PR (ed) Cytochrome 450. Structure, mechanism and biochemistry, 3rd edn. Kluwer Academic/Plenum Publishers, New YorkGoogle Scholar
  19. Guo L, Li QZ, Xia Q, Dial S, Chan PC, Fu P (2009) Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol 47:433–442CrossRefPubMedGoogle Scholar
  20. Guo L, Mei N, Lioa W, Chan PC, Fu PP (2010a) Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. OMICS 14:75–90CrossRefPubMedPubMedCentralGoogle Scholar
  21. Guo L, Shi Q, Dial S, Xia Q, Mei N, Li QZ, Chan PC, Fu P (2010b) Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies changes in drug metabolizing genes and potential mechanisms linked to kava toxicity. Food Chem Toxicol 48:686–696CrossRefPubMedGoogle Scholar
  22. Gupta D, Jalali M, Wells A, Dasgupta A (2002) Drug-herb interactions: unexpected suppression of free danshen concentrations by salicylate. J Clin Lab Anal 16:293–294CrossRefGoogle Scholar
  23. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CY (2005a) Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John’s wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 22:525–539CrossRefPubMedPubMedCentralGoogle Scholar
  24. Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A (2005b) In vivo effects of goldenseal, kava kava, black cohosh and valerian on human cytochrome P450 1A2, 2D6, 2E1 and 3A4 phenotypes. Clin Pharmacol Ther 77:415–426CrossRefPubMedPubMedCentralGoogle Scholar
  25. Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song PF, Hubbard MA, Tong Y, Cheboyina S (2006) Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifugaq racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 34:69–74CrossRefPubMedGoogle Scholar
  26. Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone GW, Hartsfield F, Tong Y, Carrier DJ, Cheboyina S, Battu SK (2008) Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort and echinacea. Mol Nutr Food Res 52:1–9Google Scholar
  27. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM (2001) Variability in commercial ginseng products: an analysis of 25. Clin Nutr 73:1101–1106Google Scholar
  28. Hellum BH, Nilsen OG (2008) In vitro inhibition of CYP3A4 metabolism and P-glycoprotein mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 102:466–475CrossRefPubMedGoogle Scholar
  29. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002) St. John’s wort (hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 54:349–356CrossRefPubMedPubMedCentralGoogle Scholar
  30. Hennessy M, Spiers JP (2007) A primer on the mechanics of P-glycportein the multidrug transporter. Pharmacol Res 55:1–15CrossRefPubMedGoogle Scholar
  31. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J (2002) St. Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Pharmacol 53:75–82CrossRefGoogle Scholar
  32. Izzo AA, Ernst E (2009) Interactions between herbal medicines and prescribed drugs. An updated systematic review. Drugs 69:1777–1798CrossRefPubMedGoogle Scholar
  33. Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BO, Duke CC, Day RO, Mclachlan AJ (2005) Effect of ginkgo and ginger on the pharmacokientics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 59:425–432CrossRefPubMedPubMedCentralGoogle Scholar
  34. Johansson B, Kindmark C, Trell E, Wollheim F (1972) Sequential changes of plasma proteins after myocardial infarction. Scand J Clin Lab Investig 124:117–126CrossRefGoogle Scholar
  35. Kay L, Kampmann JP, Svendsen TL, Vergman B, Hansen JEM, Skovsted L, Kristensen M (1985) Influence of rifampicin and isoniazid on the kinetics of phenytoin. Br J Clin Pharmacol 20:323–326CrossRefPubMedPubMedCentralGoogle Scholar
  36. Lefebvre T, Foster BC (2004) In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharmacol Pharm Sci 7:265–273Google Scholar
  37. Liu KH, Kim MJ, Jeon BH, Shon JH, Cha IJ, Cho KH, Lee SS, Shin JG (2006) Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J Clin Pharm Ther 31:83–91CrossRefPubMedGoogle Scholar
  38. Maclennan AH, Wilson DH, Taylor AW (2002) The escalating cost and prevalence of alternative medicine. Preventative Med 35:166–173CrossRefGoogle Scholar
  39. Nathan P (1999) The experimental and clinical pharmacology of St. John’s Wort (hypericum perforatum L.). Mol Psychiatry 4:333–338CrossRefPubMedGoogle Scholar
  40. Nelson DR (2009) The cytochrome P450 homepage. Hum Genomics 4(1):59–65Google Scholar
  41. Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ (1981) Diazepam interaction with antituberculosis drugs. Clin Pharmacol Ther 29:671–678CrossRefPubMedGoogle Scholar
  42. Pelkonen OP, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H (2008) Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 82:667–715CrossRefPubMedGoogle Scholar
  43. Perloff MD, Von Moltke LL, Störmer E, Shader RI, Greenblatt DJ (2001) St. John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 134:1601–1608CrossRefPubMedPubMedCentralGoogle Scholar
  44. Perucca E, Crema A (1982) Plasma protein binding of drugs during pregnancy. Clin Pharmacokinet 7:336–352CrossRefPubMedGoogle Scholar
  45. Rendic S (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev 34:83–448CrossRefPubMedGoogle Scholar
  46. Robinson MM, Zhang X (2011) Traditional medicines: global situation, issues and challenges. In: WHO/EMP/MIE (ed) The world medicines situation 2011. World Health Organization, GenevaGoogle Scholar
  47. Serbouce-Hougel S, Durand G, Corbii M, Agneray J, Feger J (1981) Alterations in relative proportions of microheterogenous forms of human alpha 1-acid glycoprotein in liver disease. J Hepatol 2:245–252Google Scholar
  48. Sevior DK (2012) Complementary products and drug interactions – screening for the potential to cause pharmacokinetic interactions. Doctor of Philosophy, RMIT UniversityGoogle Scholar
  49. Sevior D, Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O, Ahokas JT (2010) Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-One cocktail. Xenobiotica 40:245–254Google Scholar
  50. Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C (2012) Pharmacovigilance of herbal medicine. J Ethnopharmacol 140:513–518CrossRefPubMedGoogle Scholar
  51. Sheridan H, Krenn L, Jiang R, Sutherland I, Ignatova S, Marmann A, Liang X, Sendker J (2012) The potential of metabolic fingerprinting as a tool for the modernization of TCM preparations. J Ethnopharmacol 140:482–491CrossRefPubMedGoogle Scholar
  52. Subehan A, Usia T, Iwata H, Kadota S, Tezuka Y (2006) Mechanism-based inhibition of CYP3A4 and CYP2D6 by Indonesian medicinal plants. J Ethnopharmacol 105:449–455CrossRefPubMedGoogle Scholar
  53. Tassaneeyakul W, Guo LQ, Fukuda K, Ohta T, Yamazoe Y (2000) Inhibition selectivity of grapefruit juice components on human cytochromes P450. Arch Biochem Biophys 378:356–363CrossRefPubMedGoogle Scholar
  54. Taylor JR, Wilt VM (1999) Probable antagonism of warfarin by green tea. Ann Pharmacother 33:426–428CrossRefPubMedGoogle Scholar
  55. Thomas KJ, Nicholl JP, Coleman P (2001) Use and expenditure on complementary medicine in England: a population based survey. Complement Ther Med 9:2–11CrossRefPubMedGoogle Scholar
  56. Voulgari F, Cummins P, Gardecki T, Beeching N, Stone P, Stuart J (1982) Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br Heart J 1982:4Google Scholar
  57. Wilk-Zasadna I, Bernasconi C, Pelkonen O, Coecke S (2015) Biotransformation in vitro: an essential consideration in the quantitative in vitro-to-iv-vivo extrapolation (QIVIVE) of toxicity data. Toxicology 332:8–19CrossRefPubMedGoogle Scholar
  58. World Health Organization (2008) Traditional medicine. WHO. http://www.who.int/mediacentre/factsheets/2003/fs134/en/
  59. Yang SO, Shin YS, Hyun SH, Cho S, Bang KH, Lee D, Choi SP, Choi HK (2012) NMR-based metabolic profiling and differentiation of ginseng roots according to cultivation ages. J Pharm Biomed Anal 58:19–26CrossRefPubMedGoogle Scholar
  60. Zanger UM, Turpeinen M, Klein K, Schwab M (2008) Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem 392:1093–1108CrossRefPubMedGoogle Scholar
  61. Zhang L, Yan J, Liu X, Ye Z, Yang X, Meyboom R, Chan K, Shaw D, Duez P (2012) Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol 140:519–525CrossRefPubMedGoogle Scholar
  62. Zhang Y, Liu C, Qi Y, Li Y, Wang L, Ren J, Tang Y (2015) Efficient combination of circulating ultrasound-assisted extraction partition chromatography for extraction and on-line separation of chemical constituents from Stellera chamaejasme L. Phytochem Anal 26:301–309CrossRefPubMedGoogle Scholar
  63. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW (2003) Interactions of herbs with cytochrome P450. Drug Metab Rev 35:35–98CrossRefPubMedGoogle Scholar
  64. Zhou S, Lim L, Chowbray B (2004a) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57–104CrossRefPubMedGoogle Scholar
  65. Zhou SF, Koh HL, Gao Y, Gong ZY, Lee EJD (2004b) Herbal bioactivation: the good, the bad and the ugly. Life Sci 74:935–968CrossRefPubMedGoogle Scholar
  66. Zhou S, Huang M, Xu A, Yang H, Duan W, Paxton JW (2005) Prediction of herb-drug metabolic interactions: a simulation study. Phytother Res 19:464–471CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2017

Authors and Affiliations

  1. 1.Department of Pharmacology and ToxicologyUniversity of OuluOuluFinland
  2. 2.School of Medical SciencesRMIT-UniversityBundooraAustralia
  3. 3.School of Medical SciencesRMIT-University, Bundoora CampusBundooraAustralia

Personalised recommendations